Search

Mara G Gerloni

from La Jolla, CA
Age ~61
Get Report
Also known as:
Mara G Pedrazzani, Erioni G Mara, Mara I
Related to:
Mere GerloniPaolo P Pedrazzani, 58
Connected to:
Gregory S Gerlovin, 42Thomas J Gerlowski, 38Tal O Gerloy, 66Carol L Gerlt, 55Jamie Gerlt, 41Jena A Gerlt, 36Renee Gerlt, 43Troy A Gerlt, 56Heath R Gerlufsen, 50James J Germack, 113

Mara Gerloni Phones & Addresses

  • La Jolla, CA
  • San Diego, CA

Resumes

Resumes

Mara Gerloni Photo 1

Chief Scientific Officer

View page
Location:
11555 Sorrento Valley Rd, San Diego, CA 92121
Industry:
Biotechnology
Work:
Bellatrix Pharmaceuticals
Chief Scientific Officer
Cosmo Bioscience May 2005 - May 2016
Chief Executive Officer
Cosmo Bioscience Apr 2002 - Apr 2005
Director of Scientific Activities
Ucsd Cancer Center 2002 - 2005
Associate Project Scientist
Ucsd Cancer Center 1998 - 2002
Assistant Project Scientist
Education:
Uc San Diego 1993 - 1997
Università Degli Studi Di Parma 1993 - 1996
Doctorates, Doctor of Philosophy, Microbiology, Virology Università Degli Studi Di Parma 1986 - 1990
Università Degli Studi Di Parma 1982 - 1986
Doctorates, Doctor of Pharmacy, Pharmacy
Skills:
Biotechnology
Start Ups
Strategic Planning
Life Sciences
Business Strategy
Immunology
Cancer Immunology
Clinical Trial
Microbiology
Virology
Micology
Chron Disease and Ibd
Cell Biology
Pharmacology
Patent
Cancer Treatment
Drug Discovery
Oncology
Clinical Research
Pharmaceutical Industry
Molecular Biology
Medical Devices
Technology Transfer
Biochemistry
In Vitro
Cell Culture
Research
Cancer
Leadership
Languages:
English
Italian
Spanish
French
Mara Gerloni Photo 2

Mara Gerloni

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Mara Gerloni
President
COSMO BIOSCIENCE, INC
Commercial Physical Research
11555 Sorrento Vly Rd STE A, San Diego, CA 92121
(858) 523-0413
Mara Gerloni
Cosmo Bio Technologies Srl LLC
Biotech/Pharmaceutical
11555 Sorrento Vly Rd, San Diego, CA 92121
Lainate (Mi), Washington, DC 20020

Publications

Us Patents

Plasmids With Immunological Action

View page
US Patent:
20120076807, Mar 29, 2012
Filed:
May 26, 2011
Appl. No.:
13/116686
Inventors:
Mara Gerloni - San Diego CA, US
Assignee:
International Investment and Patents S.A. - Charlotte
International Classification:
A61K 39/00
A61K 39/02
C12N 15/63
A61K 31/7088
A61P 37/04
A61P 33/00
A61P 31/10
A61P 31/12
A61P 31/04
C12N 15/85
A61K 39/12
A61P 35/00
US Classification:
4241851, 4241841, 4242041, 4242341, 4242651, 4242741, 4242771, 4353201, 514 44 R
Abstract:
Recombinant plasmids usable for the transfection of eukaryotic and prokaryotic cells are described; such plasmids have a length comprised between 7 and 12 kbases and comprise a sequence encoding the heavy chain of an immunoglobulin; in particular, they may be used:

Plasmids With Immunological Action

View page
US Patent:
20100040648, Feb 18, 2010
Filed:
Jul 13, 2007
Appl. No.:
12/377114
Inventors:
Mara Gerloni - San Diego CA, US
Assignee:
INTERNATIONAL INVESTMENT AND PATENTS SA - Luxembourg
International Classification:
A61K 39/00
C12N 15/00
A61K 31/7088
US Classification:
4242001, 4353201, 514 44 R, 4241841
Abstract:
Recombinant plasmids usable for the transfection of eukaryotic and prokaryotic cells are described; such plasmids have a length comprised between 7 and 12 kbases and comprise a sequence encoding the heavy chain of an immunoglobulin; in particular, they may be used:

17A-Monoesters And 17A,21-Diesters Of Cortexolone For Use In The Treatment Of Tumors

View page
US Patent:
20230128438, Apr 27, 2023
Filed:
Dec 19, 2022
Appl. No.:
18/068346
Inventors:
- Dublin 2, IE
Mara GERLONI - San Diego CA, US
Assignee:
COSMO TECHNOLOGIES LTD. - Dublin 2
International Classification:
A61K 31/573
C07J 5/00
A61K 9/00
A61K 45/06
Abstract:
The present invention relates to certain cortexolone derivatives of formula (I)and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of the pharmaceutical compositions as antitumor medicinal products.

17A-Monoesters And 17A,21-Diesters Of Cortexolone For Use In The Treatment Of Tumors

View page
US Patent:
20210299145, Sep 30, 2021
Filed:
Apr 6, 2021
Appl. No.:
17/223776
Inventors:
- Dublin, IE
Mara GERLONI - San Diego CA, US
Assignee:
COSMO TECHNOLOGIES LTD. - Dublin
International Classification:
A61K 31/573
C07J 5/00
A61K 9/00
A61K 45/06
Abstract:
The present invention relates to certain cortexolone derivatives of formula (I)and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of the pharmaceutical compositions as antitumor medicinal products.

17A-Monoesters And 17A,21-Diesters Of Cortexolone For Use In The Treatment Of Tumors

View page
US Patent:
20200215080, Jul 9, 2020
Filed:
Mar 16, 2020
Appl. No.:
16/820407
Inventors:
- Dublin 2, IE
Mara GERLONI - San Diego CA, US
Assignee:
COSMO TECHNOLOGIES LTD. - Dublin 2
International Classification:
A61K 31/573
C07J 5/00
A61K 9/00
A61K 45/06
Abstract:
The present invention relates to certain cortexolone derivatives of formula (I)and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of the pharmaceutical compositions as antitumor medicinal products.

17Alpha-Monoesters Of Cortexolone For Use In The Treatment Of Tumors

View page
US Patent:
20190175618, Jun 13, 2019
Filed:
Feb 12, 2019
Appl. No.:
16/273575
Inventors:
- Dublin 2, IE
Mara GERLONI - San Diego CA, US
Assignee:
COSMO TECHNOLOGIES LTD. - Dublin 2
International Classification:
A61K 31/573
A61K 45/06
C07J 5/00
A61K 9/00
Abstract:
The present invention provides certain cortexolone derivatives, and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also provides pharmaceutical compositions comprising the cortexolone derivatives as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.

17A-Monoesters And 17A,21-Diesters Of Cortexolone For Use In The Treatment Of Tumors

View page
US Patent:
20190091240, Mar 28, 2019
Filed:
Nov 23, 2018
Appl. No.:
16/199015
Inventors:
- Dublin 2, IE
Mara GERLONI - San Diego CA, US
Assignee:
COSMO TECHNOLOGIES LTD. - Dublin 2
International Classification:
A61K 31/573
C07J 5/00
A61K 9/00
A61K 45/06
Abstract:
The present invention relates to certain cortexolone derivatives of formula (I)and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of the pharmaceutical compositions as antitumor medicinal products.

Cortexolone 17Alpha-Benzoate For Use In The Treatment Of Tumours

View page
US Patent:
20170360806, Dec 21, 2017
Filed:
Oct 7, 2015
Appl. No.:
15/517659
Inventors:
- Dublin, IE
Mara GERLONI - San Diego CA, US
International Classification:
A61K 31/573
A61K 9/00
A61K 45/06
Abstract:
The present invention provides certain cortexolone derivatives of formula (I), and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.
Control profile
Mara G Gerloni from La Jolla, CA, age ~61 Get Report